Combination of a PI3K-and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer

被引：1
|
作者：
Wulf, Gerburg M. [1 ]
Juvekar, Ashish [1 ]
Lyssiotis, Costas A. [2 ]
Hu, Hai [1 ]
Yadegarynia, Sina [1 ]
Liu, Hui [1 ]
Kim, Baek [3 ]
Winter, Eric [4 ]
Scully, Ralph [1 ]
Asara, John [1 ]
Cantley, Lewis C. [2 ]
Matulonis, Ursula [4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Weill Cornell Med Sch, New York, NY USA
[3] Emory Sch Med, Atlanta, GA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT338
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT338
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer
    Amr Ahmed El-Arabey
    Mohnad Abdalla
    Human Cell, 2022, 35 : 1298 - 1300
  • [2] The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer
    El-Arabey, Amr Ahmed
    Abdalla, Mohnad
    HUMAN CELL, 2022, 35 (04) : 1298 - 1300
  • [3] Analysis of resistance to the combination of a PI3K-and Parp-inhibitor using a genomic sequencing approach
    Nabavi, Sheida
    Juvekar, Ashish
    Wang, Nicholas
    Cantley, Lewis C.
    Wulf, Gerburg M.
    CANCER RESEARCH, 2016, 76
  • [4] Patient-reported quality of life during PARP-inhibitor treatment for high-grade serous ovarian cancer
    Philp, Lauren
    Eisenhauer, Eric
    Bregar, Amy
    del Carmen, Marcela
    Goodman, Annekathryn
    Randall, Thomas
    Mazina, Varvara
    Hubbell, Harrison
    Sisodia, Rachel
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S232 - S232
  • [5] Characterization of PARP inhibitor combination therapies in triple-negative breast cancer
    Fyle, Elicia
    Abdesselam, Djihane
    Frederick, Mallory
    Hassan, Saima N.
    CANCER RESEARCH, 2023, 84 (06)
  • [6] AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines
    Perez-Fidalgo, Jose Alejandro
    Martinez Pretel, Juan Jose
    Sanchez Serrano, Paloma
    Heredia, Victoria
    Hochstadt, Jan
    Mendiola, Marta
    Redondo, Andres
    Gonzalez Villena, Lidia
    Ruiz Linuesa, Miriam
    Pineda, Begona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
    Lonning, Per E.
    Nikolaienko, Oleksii
    Pan, Kathy
    Kurian, Allison W.
    Eikesdal, Hans P.
    Pettinger, Mary
    Anderson, Garnet L.
    Prentice, Ross L.
    Chlebowski, Rowan T.
    Knappskog, Stian
    JAMA ONCOLOGY, 2022, 8 (11) : 1579 - 1587
  • [8] Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer.
    Batalini, Felipe
    Gulhan, Doga
    Mao, Victor
    Polak, Madeline
    Winer, Eric P.
    Mayer, Erica L.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    Park, Peter
    Wulf, Gerburg M.
    CANCER RESEARCH, 2021, 81 (13)
  • [9] New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma
    Puzyrenko, Andrii
    Cortina, Chandler S.
    Jorns, Julie M.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2022, 30 (07) : 728 - 733
  • [10] Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.
    Lonning, Per Eystein
    Nikolaienko, Oleksii
    Pan, Kathy
    Kurian, Allison W.
    Eikesdal, Hans Petter Petter
    Pettinger, Mary
    Anderson, Garnet L.
    Prentice, Ross L.
    Chlebowski, Rowan T.
    Knappskog, Stian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345